A Randomized Phase 2 Study of Cediranib in Combination with Olaparib versus
Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer
«The findings of this study are exciting because they support the idea that combining these two targeted oral therapies results in significant activity in ovarian cancer, more so than
olaparib alone,» said Joyce Liu, M.D., MPH, the lead investigator and medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana - Farber Cancer Institute, Boston.
The trial compared the activity of the combination of the drug olaparib, which blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs.
olaparib alone.
Not exact matches
In tumors formed by human breast cancer cells, DNA damage (brown staining) is increased by simultaneous
Olaparib treatment and PGAM1 suppression (right) when compared to either
Olaparib treatment (left) or PGAM1 suppression (center)
alone.
A Phase II Study of the PARP Inhibitor
Olaparib (AZD2281)
Alone and in Combination with AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors - OLAPCO (
OLAParib COmbinations)